Defunct Company
Total Trials
11
As Lead Sponsor
As Collaborator
0
Total Enrollment
785
NCT00232726
Clinical Study of Previously Untreated Patients With Malignant Melanoma
Phase: Phase 2
Role: Lead Sponsor
Start: Sep 30, 2005
Completion: Jul 31, 2007
NCT00405743
A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies
Phase: Phase 1/2
Start: May 31, 2006
Completion: May 31, 2010
NCT00498836
Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma
Start: Mar 31, 2007
Completion: Oct 31, 2008
NCT00498407
A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer
Start: May 31, 2007
Completion: Dec 31, 2008
NCT00831636
A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer
Start: Apr 30, 2008
Completion: Apr 30, 2010
NCT00778128
A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour
Phase: Phase 1
Start: Oct 31, 2008
NCT00913198
A Study of CP-4126 in Patients With Advanced Pancreatic Cancer
Start: Apr 30, 2009
Completion: Sep 30, 2011
NCT01035502
A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
Start: Dec 31, 2009
Completion: Jun 30, 2013
NCT01147939
Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML)
Phase: Phase 3
Start: Jun 30, 2010
NCT01258816
The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055)
Start: Oct 31, 2010
NCT01783964
Elacytarabine Mass Balance Study in Healthy Volunteers
Start: Feb 28, 2013